Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects

Vaccination toward SARS-CoV-2 reduced mortality and 'boosters' are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home "San Giuseppe Mosc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Human vaccines & immunotherapeutics Jg. 18; H. 5; S. 2060018
Hauptverfasser:	Borgonovo, Fabio, Stangalini, Carlo Alberto, Tinelli, Carmine, Mariani, Chiara, Mileto, Davide, Cossu, Maria Vittoria, Abbati, Laura, Bilardo, Lara, Gagliardi, Gloria, Cutrera, Miriam, Pellicciotta, Martina, Armiento, Luciana, Dedivitiis, Gianfranco, Capetti, Amedeo F., Rizzardini, Giuliano
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Taylor & Francis 30.11.2022 Taylor & Francis Group
Schlagworte:	Aged Antibodies, Viral antibody BNT162 Vaccine Brief Report Coronavirus – Short Report covid-19 COVID-19 - prevention & control decline Humans igg Immunoglobulin G kinetics SARS-CoV-2 spike Vaccination vaccine COVID-19 SARS-CoV-2 vaccine antibody IgG decline kinetics spike
ISSN:	2164-5515, 2164-554X, 2164-554X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!